Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment.

• Publication year

  2018

• Venue

  Molecular Cancer

• Publication date

  2018-02-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s12943-018-0777-1PMID 29455650PMCID 5817870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olmutinib‐induced palmoplantar keratoderma

  2018cited by this paper
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017influential reference
• Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

  2017cited by this paper
• Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

  2017cited by this paper
• Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

  2017cited by this paper
• Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

  2017cited by this paper
• A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

  2017cited by this paper
• Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

  2017cited by this paper
• MET amplification (amp) as a resistance mechanism to osimertinib.

  2017cited by this paper
• Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017influential reference
• Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

  2017cited by this paper
• Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation

  2017cited by this paper
• Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

  2017cited by this paper
• Tracking the Evolution of Non‐Small‐Cell Lung Cancer

  2017cited by this paper
• Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

  2017cited by this paper
• Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

  2017cited by this paper
• MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

  2017cited by this paper
• Liquid biopsy genotyping in lung cancer: ready for clinical utility?

  2017cited by this paper
• Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

  2017cited by this paper
• Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

  2017cited by this paper
• The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome

  2017cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.

  2016cited by this paper
• Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

  2016cited by this paper
• Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

  2016cited by this paper
• Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation‐positive advanced non‐small cell lung cancer (aNSCLC): 134O_PR

  2016cited by this paper
• Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

  2016cited by this paper
• First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

  2016cited by this paper
• Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

  2016cited by this paper
• EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

  2016cited by this paper
• Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

  2016cited by this paper
• A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

  2016cited by this paper
• Osimertinib (AZD9291) in pre‐treated pts with T790M‐positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results: LBA2_PR

  2016cited by this paper
• Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Update to Rociletinib Data with the RECIST Confirmed Response Rate.

  2016influential reference
• Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

  2016cited by this paper
• Feasibility of cell-free circulating tumor DNA testing for lung cancer.

  2016cited by this paper
• Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer.

  2016cited by this paper
• Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300

  2016cited by this paper
• Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

  2016cited by this paper
• BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

  2016cited by this paper
• Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

  2016cited by this paper
• Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

  2016influential reference
• Cancer treatment and survivorship statistics, 2016

  2016cited by this paper
• Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

  2016influential reference
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

  2016cited by this paper
• Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015influential reference
• Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

  2015influential reference
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

  2015cited by this paper
• Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

  2015influential reference
• Rociletinib in EGFR-mutated non-small-cell lung cancer.

  2015cited by this paper
• Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291

  2015cited by this paper
• Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

  2015cited by this paper
• A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies.

  2015cited by this paper
• The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

  2015cited by this paper
• Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

  2015cited by this paper
• RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

  2015cited by this paper
• Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

  2015cited by this paper
• Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

  2015influential reference
• Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

  2015cited by this paper
• Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

  2015cited by this paper
• Overcoming resistance to targeted therapy for lung cancer.

  2015cited by this paper
• Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor

  2014cited by this paper
• In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Small Molecule Therapeutics In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

  2014cited by this paper
• Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

  2014cited by this paper
• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

  2014cited by this paper
• Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

  2014cited by this paper
• Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

  2014cited by this paper
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

  2014influential reference
• Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

  2014cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases

  2013cited by this paper
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  2013cited by this paper
• Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping

  2013cited by this paper
• Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

  2013cited by this paper
• Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

  2013cited by this paper
• Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations

  2012cited by this paper
• Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

  2012cited by this paper
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

  2012cited by this paper
• Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.

  2012cited by this paper
• Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer

  2012cited by this paper

• Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study

  2026cites this paper
• Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review

  2026cites this paper
• Evaluation of the efficacy as well as prognosis of targeted therapy for advanced non-small cell lung cancer patients with different expression of miR-183 family in body fluids

  2026cites this paper
• SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44

  2026cites this paper
• Alisol B 23-acetate as a promising natural bioactive tetracyclic triterpenoid: A review of its extraction methods, pharmacokinetics, metabolism, pharmacology, and toxicity.

  2026cites this paper
• 2025 Taiwan guidelines on the drug therapy of lung cancer: Advanced non-squamous cell carcinoma with actionable oncogenic drivers.

  2026cites this paper
• Chemical Probes Derived from Third-Generation EGFR-TKIs as Potential Companion Diagnostic Tools for Targeted Therapy.

  2026cites this paper
• Non-immobilized graphene oxide–based screening of aptamers for non-small cell lung cancer (NSCLC) drug resistance biomarkers and development of a nano-detection platform

  2026cites this paper
• First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

  2026cites this paper
• Immunotherapy after EGFR-TKI treatment in advanced non-small cell lung cancer: Current status and future perspectives (Review)

  2026cites this paper
• The application development of nanoparticle-based drug delivery systems in combating drug resistance of lung cancer

  2026cites this paper
• Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics

  2025cites this paper
• Targeting Growth Hormone Receptor to Overcome Therapy Resistance in Non-Small Cell Lung Cancer

  2025cites this paper
• EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC‐ and Furmonertinib‐Based Treatment: A Case Report

  2025cites this paper
• Baicalin inhibits A549 cells proliferation and EMT through targeting the EGFR pathway.

  2025cites this paper
• IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer

  2025cites this paper
• Antibody–drug conjugate: a newly developed biological missile for tumor treatment

  2025cites this paper
• Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer

  2025cites this paper
• Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945

  2025cites this paper
• Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

  2025cites this paper
• Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations

  2025cites this paper
• S100A6 Induces the Resistance to Gefitinib in Human Lung Adenocarcinoma PC9 Cell Lines with EGFR 19 Exon Mutations

  2025cites this paper
• Separase Inhibition Enhances Gefitinib Sensitivity of Lung Cancer via PTBP1/TAK1/RIPK1‐Mediated PANoptosis

  2025cites this paper
• Asaraldehyde suppresses non-small cell lung cancer progression via ferroptosis induction and inhibition of PI3K-AKT signaling.

  2025cites this paper
• Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort

  2025cites this paper
• Efficacy and Safety of Different Dosages of Anlotinib Combined with PD-1 Monoclonal Antibody in the Treatment of Advanced Non-Small Cell Lung Cancer

  2025cites this paper
• Pyrene-Based Amphiphilic Fluorescent Probe as a Versatile Optical Platform for Cardiac Biomarker Detection: From Biological Fluids to Live Cell Imaging.

  2025cites this paper
• Effects of exosomes from different origins on osteoclasts

  2025cites this paper
• Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma

  2025cites this paper
• Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer

  2025cites this paper
• FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation

  2025cites this paper
• Nanotechnology‐Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives

  2025cites this paper
• Predicting the Impact of Drug Resistance Mutations on Inhibitor Potency with Molecular Dynamics and Machine Learning.

  2025cites this paper
• Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs

  2025cites this paper
• Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

  2025cites this paper
• Comprehensive analysis indicates DDX46 as a novel biomarker for the prognosis of lung adenocarcinoma

  2025cites this paper
• RBM14 enhances transcriptional activity of p23 regulating CXCL1 expression to induce lung cancer metastasis

  2025cites this paper
• The Impact of Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer with EGFR Mutation: Survival Analysis of a Retrospective Cohort Study

  2025cites this paper
• Calcium triggers calmodulin degradation to induce EGF receptor instability and overcome non-small cell lung cancer resistance to tyrosine kinase inhibitors

  2025cites this paper
• HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer

  2025cites this paper
• The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer

  2025cites this paper
• GPM6B inhibits tumor progression by targeting HPGD in lung adenocarcinoma

  2025cites this paper
• Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations

  2025cites this paper
• Integrative bulk RNA analysis unveils immune evasion mechanisms and predictive biomarkers of osimertinib resistance in non-small cell lung cancer

  2025cites this paper
• A Molecular Genetic Registry as a Tool for Personalized Treatment of Non-small Cell Lung Cancer

  2025cites this paper
• Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability

  2025cites this paper
• Identifying circRNA-miRNA-mRNA Networks Associated with Osimertinib Resistance in Lung Adenocarcinoma by Analyzing Microarray Datasets.

  2025cites this paper
• Hypoxia-induced exosomal LUCAT1 promotes osimertinib resistance in lung adenocarcinoma by stabilizing c-MET

  2025cites this paper
• SuFu somatic mutations are recognized as novel markers for genomic instability and tumor growth in lung adenocarcinoma

  2025cites this paper
• Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer.

  2025cites this paper
• Magnolin overcomes EGFR TKI resistance in NSCLC by modulation of NDRG1-NRG2-HECW1 pathway

  2025cites this paper
• Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis

  2025cites this paper
• Dual inhibition of angiogenesis by Peucedanum praeruptorum Dunn root extract in endothelial and gefitinib-resistant lung cancer cells.

  2025cites this paper
• Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy.

  2025cites this paper
• Acute Interstitial Pneumonia Caused by Dual-Target Therapy in Resistant EGFR-Mutated Lung Adenocarcinoma: A Case Report and Literature Review

  2025cites this paper
• A biomimetic liposome platform targeting non-small cell lung cancer to modulate the inflammatory and metabolic microenvironment for enhanced therapy

  2025cites this paper
• Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness

  2025cites this paper
• ASIC3-PLCG1 Axis-Driven Macropinocytosis Promotes Osimertinib Drug-Tolerant Persistence in Malignant Pleural Effusion-Associated NSCLC.

  2025cites this paper
• Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023

  2025cites this paper
• Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis.

  2025cites this paper
• Genome-wide CRISPR-Cas9 screening identifies ITGA8 responsible for abivertinib sensitivity in lung adenocarcinoma

  2025cites this paper
• Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells

  2025cites this paper
• Epigenetic code underlying EGFR-TKI resistance in non-small-cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies.

  2025cites this paper
• Rapamycin combined with osimertinib alleviated non-small cell lung cancer by regulating the PARP, Akt/mTOR, and MAPK/ERK signaling pathways

  2025cites this paper
• A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

  2025cites this paper
• Natural products combating EGFR-TKIs resistance in cancer

  2025cites this paper
• Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review

  2025cites this paper
• Decoding driver and phenotypic genes in cancer: Unveiling the essence behind the phenomenon.

  2025cites this paper
• Discovery of novel small molecules targeting TGF-β signaling for the treatment of non-small cell lung cancer.

  2025cites this paper
• Lung Adenocarcinoma With Initially Co‐Occurring EGFR and BRAF Double Mutation: A Case Report and Literature Review

  2025cites this paper
• Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma

  2025cites this paper
• Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based on 18F-FDG PET and thin-section CT radiomics with machine learning

  2025cites this paper
• Clinicopathologic features of histologic transformation in lung adenocarcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

  2025cites this paper
• Cytotoxic Effect of Escitalopram/Etoposide Combination on Etoposide-Resistant Lung Cancer

  2025cites this paper
• Inhibition of NSUN3 suppresses immune escape in non-small cell lung cancer through stabilizing PD-L1 in a 5-methyladenosine dependent way

  2025cites this paper
• In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID

  2025cites this paper
• Prediction of EGFR Mutations in Lung Adenocarcinoma via CT Images: A Comparative Study of Intratumoral and Peritumoral Radiomics, Deep Learning, and Fusion Models.

  2025cites this paper
• Downregulation of PAQR3 expression predicts poor prognosis of patients with pan-cancer: a meta-analysis

  2025cites this paper
• EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study

  2025cites this paper
• Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis

  2025cites this paper
• Bispecific antibody for lung cancer: mechanisms and clinical insights

  2025cites this paper
• PathGene: Benchmarking Driver Gene Mutations and Exon Prediction Using Multicenter Lung Cancer Histopathology Image Dataset

  2025cites this paper
• Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis

  2025cites this paper
• Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

  2025cites this paper
• Severe hypotension induced by Almonertinib: a case report with literature review and clinical insights

  2025cites this paper
• Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced EGFR-mutant NSCLC with Primary Resistance to EGFR-TKIs：a retrospective cohort Study.

  2025cites this paper
• Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance.

  2025cites this paper
• Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790M

  2025cites this paper
• Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

  2025cites this paper
• BRINP3 promotes lung adenocarcinoma by enhancing CLOCK-mediated transcriptional regulation of CRYZL1 and activating the AKT pathway.

  2025cites this paper
• Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Targeting the SYVN1-EGFR axis: a breakthrough strategy for TKI-resistant NSCLC

  2025cites this paper
• 5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma

  2025cites this paper
• Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs

  2025cites this paper
• Transformation from acquired EGFR 19del/C797S to EGFR 19del/T790M in an advanced non-small cell lung cancer patient: a case report and literature review

  2025cites this paper
• Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  2025cites this paper
• Membrane cholesterol-dependent dual VEGFR2/FGFR1 inhibition by ginsenoside Rg3 to overcome gefitinib resistance in NSCLC.

  2025cites this paper
• MiR-493–3p suppresses the DPY-30 histone methyltransferase complex regulatory subunit to attenuate gefitinib resistance in lung cancer

  2025cites this paper
• ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer

  2025cites this paper
• Proteolysis-Targeting Chimera-Doxorubicin Conjugate Nanoassemblies for Dual Treatment of EGFR-TKI Sensitive and Resistant Non-Small Cell Lung Cancer.

  2025cites this paper